As GLP-1 Drugs Change How People Eat, Drugmakers Collect and Snack Makers Feel the Squeeze
2026-10-11 09:15
•Matthew Benjamin •The Motley Fool
••••• ••••••• Axe Cap view
GLP-1 Drugs Reshape Consumer Habits: What It Means for SA Investors
Weight-loss drugs disrupt global snack sales but present select pharmaceutical and consumer opportunities for South African portfolios.
The rise of GLP-1 weight-loss drugs like Wegovy is causing American consumers to cut down on processed snacks by up to 8%. Globally, companies like Eli Lilly and Novo Nordisk are booming, yet some snacks and beverage giants struggle. While this might appear distant for South African investors, the ripple effects matter. The rand’s USD/ZAR rate often reacts to U.S. consumer shifts, as SA’s export-dependent economy feels changes in global demand. Closer to home, food retailers such as Shoprite and Woolworths could see modest margin pressure if SA consumers begin to mirror U.S. dietary trends. Pharma-heavyweights like Aspen and Adcock Ingram don’t have direct GLP-1 exposure, but large-cap stocks with diversified global earnings, like Naspers and Prosus, might offer steadier footing amid USD volatility. Watching USD/ZAR is critical here, as a stronger dollar could offset some consumer weakness locally. This trade-off makes investing in local consumer stocks a selective play, and the read-through to some banks—Standard Bank, FirstRand—could come via credit quality shifts if consumer spending slows. Our call could be wrong if GLP-1 adoption in SA remains low or consumer habits diverge from the U.S. experience. this is just our opinion and not financial advice
Prefer a cautious, selective approach: trim exposure to local consumer retailers while watching USD/ZAR gains to tilt toward Naspers or Prosus. Keep quality banks like Standard Bank on watch for credit impact but avoid outright speculative consumer bets.
- USD/ZAR
- Naspers
- Standard Bank
- Shoprite
- Low GLP-1 drug adoption in South Africa
- Rand volatility due to global economic shocks
6/10
GLP-1 weight-loss drugs like Wegovy and Zepbound are rapidly gaining adoption, with 11% of U.S. adults now using them. This is benefiting drug manufacturers Eli Lilly and Novo Nordisk, whose sales are surging. However, snack and beverage companies face headwinds as GLP-1 users reduce grocery spending by 5-8%, particularly on processed snacks. While some companies like Coca-Cola and Monster Beverage are weathering the impact due to their low-calorie portfolios, others like PepsiCo and Hershey are experiencing declining sales.
Our take is based on reporting first published by The Motley Fool.